Prestige Consumer Healthcare Inc Reports Q1 Fiscal Year 2025 Financial Results
Intellectia.AI1970-01-01
Prestige Consumer Healthcare Inc. Reports Q1 Fiscal Year 2025 Financial Results
Prestige Consumer Healthcare Inc. (PBH) has announced its financial results for the first quarter ended June 30, 2024.
Key Financial Metrics:
| Metric | Q1 FY 2025 | Q1 FY 2024 | Year-over-Year | Consensus Estimates |
|---|---|---|---|---|
| Total Revenue | $267.1M | $279.3M | -4.4% | $260.41M |
| Earnings per Share (EPS) | N/A | N/A | N/A | $0.86 |
Interpretation: Prestige Consumer Healthcare's revenue for Q1 FY 2025 has decreased by 4.4% compared to the same quarter last year, missing the Wall Street consensus estimate of $260.41M. The earnings per share (EPS) information was not provided, making a detailed EPS comparison difficult.
Revenue Performance by Segment:
| Segment | Q1 FY 2025 Revenue | Q1 FY 2024 Revenue | Year-over-Year Change |
|---|---|---|---|
| North American OTC Healthcare | $231.3M | $245.1M | -5.6% |
| International OTC Healthcare | $35.8M | $34.1M | +5.0% |
Interpretation: The North American OTC Healthcare segment experienced a decline of 5.6% in revenue year-over-year, primarily driven by decreased sales in the Cough & Cold and Women’s Health categories. The International OTC Healthcare segment saw a growth of 5.0%, primarily due to increased sales in the Gastrointestinal and Eye & Ear Care categories, although this was partially offset by a decrease in the Women's Health category.
Dividends and Share Repurchase Program:
On May 6, 2024, Prestige Consumer Healthcare’s Board of Directors authorized the repurchase of up to $300.0 million of the company's issued and outstanding common stock. During the three months ended June 30, 2024, 401,111 shares were repurchased under this program.
Stock Price Movement:
The stock price saw a marginal decrease of -0.35% following the release of the earnings report.
Summary:
Prestige Consumer Healthcare Inc. reported a mixed set of results for Q1 FY 2025. The revenue slightly decreased year-over-year and did not meet the consensus estimates. The North American OTC Healthcare segment saw a decline, while the International segment posted modest growth. The company continued its share repurchase program but did not provide forward guidance. The stock price reacted slightly negatively, with a small decrease post-earning release.
The report has been organized into a more readable format, and unnecessary sections have been removed.
Tesla's Robotaxi Launch Sparks New Market Momentum: What Investors Need to Know
Great News for Lucid Investors: Is Now the Time to Buy Lucid Stock?
Exploring IonQ Stock: Is This Quantum Computing Pioneer a Smart Investment?
Share